EW News and Press, Edwards Lifesciences Corporation From 05/11/22

The release of Shockwave C² is a similar event to TAVRs for Edwards Lifesciences. Considering the cardiovascular industry tailwinds, the unique niche in calcified stenosis, and safety profile should allow a similar growth trajectory for SWAV. A tremendous earnings report...

Fisher's 13F portfolio value decreased from ~$179B to ~$165B in Q1 2022. Nvidia, Intuit, Broadcom, Verizon, Uber, AMD, & Meta Platforms were increased while reducing Intel, Walmart, Walt Disney, Cisco, UnitedHealth, Starbucks & Visa this quarter. The top three positions ar...

IYH gained 12% during 7 weeks from February 22, and then fell by 9% in the next 3 weeks. IYH posted strong price returns over the medium and long term, but generated 1% yield. Biotechnology and Life Sciences Tools & Services companies historically had cyclical price movements,...

Image source: The Motley Fool. Edwards Lifesciences (NYSE: EW) Q1 2022 Earnings Call Apr 26, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Edwards Lifesciences (EW) Q1 2022 Earnings Call Transcript

Edwards Lifesciences Corporation (EW) Q1 2022 Earnings Conference Call April 26, 2022 05:00 PM ET Company Participants Mark Wilterding - Vice President, Investor Relations & Treasurer Mike Mussallem - Chairman & Chief Executive Officer Scott Ullem - Chief Financial Officer Conference ...

Shares of Edward Lifesciences' (NYSE:EW) are down 4% in after-hours trading even though its Q1 2022 net income increased ~10% year over year. In addition, the the heart-focused medical device maker beat on the top and bottom lines. Net income in the quarter rose to $373.6M ($0.39 diluted earn...

Edwards Lifesciences press release (NYSE:EW): Q1 Non-GAAP EPS of $0.60 beats by $0.03. Revenue of $1.34B (+9.8% Y/Y) beats by $30M. Q1 TAVR sales grew 11 percent; underlying 14 percent Overall, the company is reaffirming sales guidance for all product groups.  Full year 2022 sales are ex...

EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS PR Newswire IRVINE, Calif. , April 26, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2022. First Quarter Hi...

Edwards Lifesciences (NYSE:EW) is scheduled to announce Q1 earnings results on Tuesday, April 26th, after market close. The consensus EPS Estimate is $0.57 (+5.6% Y/Y) and the consensus Revenue Estimate is $1.31B (+7.4% Y/Y). Over the last 2 years, EW has beaten EPS estimates 63% of the time ...

Abiomed (NASDAQ:ABMD) and AtriCure (NASDAQ:ATRC) were among some of the healthcare equipment makers to earn bullish views at Piper Sandler after the Centers for Medicare and Medicaid Services (CMS) issued its annual Inpatient Prospective Payment System (IPPS) proposed rule on Monday...